PureTech Founded Entity Seaport Therapeutics Announces Publication in Science Translational Medicine Featuring GlyphAllo (SPT-300) ...

CEO Heather Turner told investors the company is positioned for a series of “clinically meaningful value creating catalysts” following its most recent financing, with multiple late-stage readouts plan ...

Neuronetics, Inc. 2026 turnaround? New CEO Dan Reuvers and the Greenbrook deal drove revenue growth—see key valuation and ...

Nexstim’s NBS System 6 gains FDA clearance for treatment of Adolescent Depression. Nexstim Plc ("Nexstim" or "Company") anno ...

Clifton Blake’s Private Mortgage Income Fund Trust positions itself as a fixed-income alternative for investors seeking capital preservation and steady returns, delivering consistent performance for ...

As we prepare for a future with more caregivers and more complex patient needs, let’s commit to valuing the care that happens outside hospitals just as much as the care within them. The new Blueprint ...

Detailed price information for SPDR S&P Midcap International (MDD-A) from The Globe and Mail including charting and trades.

The global investment environment has become increasingly complex, shaped by geopolitical tensions, technological disruption ...

TONMYA™ (cyclobenzaprine HCl sublingual tablets) launched November 17, 2025, for the treatment of fibromyalgia; through February 27, 2026, more ...

Dr. Robert Lenz brings over 20 years of experience in neuroscience drug development. NEW YORK, March 09, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” ...

TONMYA (cyclobenzaprine HCl sublingual tablets) launched November 17, 2025, for the treatment of fibromyalgia; through February 27, 2026, more than 1,500 healthcare providers have prescribed TONMYA to ...

And thanks for Stifel for having us here this afternoon. So yes, if I look at 2026 as we exited the prior year, we're entering this year, with a great deal of enterprise-wide momentum, and this comes ...